Literature DB >> 15173604

Nitric oxide (NO)-releasing statin derivatives, a class of drugs showing enhanced antiproliferative and antiinflammatory properties.

Ennio Ongini1, Francesco Impagnatiello, Albino Bonazzi, Massimiliano Guzzetta, Mirco Govoni, Angela Monopoli, Piero Del Soldato, Louis J Ignarro.   

Abstract

Inhibitors of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase, namely statins, exert pleiotropic actions beyond lipid-lowering effects. Their pharmacological activity on atherosclerotic plaque stability and vascular inflammation appears to be mediated, at least in part, by nitric oxide (NO). With the aim of enhancing the nonlipid-lowering properties of selected statins, we introduced a NO-releasing moiety into the structure of pravastatin (NCX 6550) and fluvastatin (NCX 6553). NO release was evaluated as nitrosylhemoglobin adduct formation by using EPR spectroscopy in rat blood. Both compounds produced a linear time-dependent increase in nitrosylhemoglobin formation, which is consistent with slow NO release kinetics. In PC12 cells, unlike their native statins, both compounds stimulated cGMP formation (NCX 6550, EC(50) = 2.3 +/- 0.2 microM; NCX 6553, EC(50) = 2.7 +/- 0.2 microM). Moreover, NCX 6550 potently inhibited cell proliferation in rat aortic smooth muscle cells (IC(50) = 2.2 +/- 0.3 microM) with a mechanism that involved both the polyamine and HMG-CoA reductase signaling pathways. Hence, mevalonate or putrescine partially reverted the effects of NCX 6550 and their combination was fully effective. In RAW 264.7 murine macrophage cells stimulated with lipopolysaccharide (1 microg/ml), NCX 6550, but not pravastatin, significantly decreased inducible NO synthase and cyclooxygenase-2 protein expression as well as nitrite accumulation. All together, the data show that the previously undescribed NO-releasing statins retain HMG-CoA reductase inhibitory activity and release bioactive NO slowly. Among the additional properties, compared with native statins, the NO-releasing statins show enhanced antiinflammatory effects. Thus, NO-releasing statins represent an interesting class of drugs having potential in the therapy of disorders associated with endothelial dysfunction and vascular inflammation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15173604      PMCID: PMC420422          DOI: 10.1073/pnas.0401996101

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  36 in total

Review 1.  The dual personality of NO.

Authors:  M Colasanti; H Suzuki
Journal:  Trends Pharmacol Sci       Date:  2000-07       Impact factor: 14.819

2.  Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation.

Authors:  I Posadas; M C Terencio; I Guillén; M L Ferrándiz; J Coloma; M Payá; M J Alcaraz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-01       Impact factor: 3.000

3.  Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation.

Authors:  L J Ignarro; G M Buga; L H Wei; P M Bauer; G Wu; P del Soldato
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-20       Impact factor: 11.205

4.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.

Authors:  Y Kureishi; Z Luo; I Shiojima; A Bialik; D Fulton; D J Lefer; W C Sessa; K Walsh
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

Review 5.  Nitric oxide and the immune response.

Authors:  C Bogdan
Journal:  Nat Immunol       Date:  2001-10       Impact factor: 25.606

6.  Posttranscriptional regulation of human iNOS by the NO/cGMP pathway.

Authors:  D Pérez-Sala; E Cernuda-Morollón; M Díaz-Cazorla; F Rodríguez-Pascual; S Lamas
Journal:  Am J Physiol Renal Physiol       Date:  2001-03

7.  Nitrosylhemoglobin, an unequivocal index of nitric oxide release from nitroaspirin: in vitro and in vivo studies in the rat by ESR spectroscopy.

Authors:  M Carini; G Aldini; R Stefani; M Orioli; R M Facino
Journal:  J Pharm Biomed Anal       Date:  2001-11       Impact factor: 3.935

8.  Antiinflammatory and antiarteriosclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis.

Authors:  W Ni; K Egashira; C Kataoka; S Kitamoto; M Koyanagi; S Inoue; A Takeshita
Journal:  Circ Res       Date:  2001-08-31       Impact factor: 17.367

9.  Activation of the endothelial nitric-oxide synthase by tumor necrosis factor-alpha. A novel feedback mechanism regulating cell death.

Authors:  S Bulotta; R Barsacchi; D Rotiroti; N Borgese; E Clementi
Journal:  J Biol Chem       Date:  2000-11-20       Impact factor: 5.157

10.  NF-kappaB and AP-1 activation by nitric oxide attenuated apoptotic cell death in RAW 264.7 macrophages.

Authors:  A von Knethen; D Callsen; B Brüne
Journal:  Mol Biol Cell       Date:  1999-02       Impact factor: 4.138

View more
  20 in total

Review 1.  Recent developments in nitric oxide donor drugs.

Authors:  M R Miller; I L Megson
Journal:  Br J Pharmacol       Date:  2007-04-02       Impact factor: 8.739

Review 2.  Tissue factor and nitric oxide: a controversial relationship!

Authors:  Luci Maria SantAna Dusse; Alan J Cooper; Bashir A Lwaleed
Journal:  J Thromb Thrombolysis       Date:  2007-01-13       Impact factor: 2.300

Review 3.  Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective.

Authors:  Kejing Chen; Roland N Pittman; Aleksander S Popel
Journal:  Antioxid Redox Signal       Date:  2008-07       Impact factor: 8.401

4.  Nitric oxide-donating statin improves multiple functions of circulating angiogenic cells.

Authors:  G Mangialardi; A Monopoli; E Ongini; G Spinetti; O Fortunato; C Emanueli; P Madeddu
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 5.  Hematopoietic stem cell transplant-associated thrombotic microangiopathy: current paradigm and novel therapies.

Authors:  J Khosla; A C Yeh; T R Spitzer; B R Dey
Journal:  Bone Marrow Transplant       Date:  2017-10-02       Impact factor: 5.483

6.  Deletion of Robo4 prevents high-fat diet-induced adipose artery and systemic metabolic dysfunction.

Authors:  Tam T T Phuong; Ashley E Walker; Grant D Henson; Daniel R Machin; Dean Y Li; Anthony J Donato; Lisa A Lesniewski
Journal:  Microcirculation       Date:  2019-04-05       Impact factor: 2.628

7.  Reversal to cisplatin sensitivity in recurrent human ovarian cancer cells by NCX-4016, a nitro derivative of aspirin.

Authors:  Anna Bratasz; Nathan M Weir; Narasimham L Parinandi; Jay L Zweier; Rajagopalan Sridhar; Louis J Ignarro; Periannan Kuppusamy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-23       Impact factor: 11.205

8.  Effects of bioactive ceramics on the pathogenesis of rat vascular smooth muscle cells treated with phorbol 12-myristate 13-acetate.

Authors:  Tae-Sung Lee; Kwan-Kyu Park; Hae-Sim Cho; Young-Ae Choo; Meeyul Hwang
Journal:  J Mater Sci Mater Med       Date:  2007-10-04       Impact factor: 3.896

9.  Inhibitory effects of NO-fluvastatin on proliferation of human lens epithelial cells in vitro by modulating cell cycle regulatory proteins.

Authors:  Zhi Wang; Ruiying Gao; Qianqian Shi; Yukan Huang; Wen Chen; Kaiying Shi
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-10-10

10.  Fluvastatin attenuated the effect of expression of β1 integrin in PAN-treated podocytes by inhibiting reactive oxygen species.

Authors:  Jia Liu; Bo Zhang; Yuping Chai; Yaguang Xu; Changying Xing; Xiaoyun Wang
Journal:  Mol Cell Biochem       Date:  2014-09-21       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.